世界500強CEO訪談 第41期:強生集團韋爾登 內(nèi)外創(chuàng)新兼修(2)

So we have a lot of both formal and informal ways that we can create this environment. Probably the last thing that we do which has been very successful is we’ve created our own Internet for our scientists, so that they can go online and see what others are doing and communicate with each other. Then if there’s an interest in one area, they can get skunk work people to get together, think about those areas and work together to bring products to the market.

因此，我們有許多正式和非正式的方式創(chuàng)造這種環(huán)境。也許最后一件我們做的很成功的事情就是，我們?yōu)榭茖W家創(chuàng)造了我們自己的因 特網(wǎng)，那樣他們就可以上線看到他人在做些什么，并且可以彼此之間進行交流。如果他們對某一個領(lǐng)域產(chǎn)生了興趣，他們就可以把不同領(lǐng)域的人集合起來共同思考，并一起努力將生產(chǎn)出來的產(chǎn)品推向市場。

Reporter: What are the major challenges facing drug and healthcare companies, both in the US and abroad?

記者：無論是在美國還是在其他國家，藥材和衛(wèi)生保健公司所面臨的主要挑戰(zhàn)都有什么呢?

Weldon: If you look at the cost of health care, I think it’s a responsibility we all have to figure out how to get it under control. It’s driven by demographics. It’s driven by the aging population, the emerging middle class in other parts of the world and technology. People want to live longer, they want to live better and they want to live healthier. I think that we have a couple of responsibilities. One is to get up front and look at prevention and wellness, healthy people and how do you keep them healthy and treat them on the other end, where they need the treatment. And so the cost of health care is a big challenge. I think that the regulatory environment has become another huge challenge. People are looking for products that can be risk free. You get up in the morning and you walk across the street-that’s not risk free. So don’t think that you’re going to be able to deliver a product in a patient. Drugs by definition have good effects and side effects. I’ve had a knee replaced and you know there’s a risk associated with having your knee replaced; mine has worked out extremely well. But it could have also gone another way. There are all kinds of issues there and I think that everybody is looking for this risk free environment—and it's not risk free. There are risks associated with it. I think that we have to define them. We have to do good research. We have to look at evidence-based medicine and see what is going to come out of it. But I think that the regulatory environments have become somewhat risk averse, if you will, in trying to find out everything. And usually with patients, many times you don’t find everything out because of the way somebody may use a product or what not.

韋爾登：如果去看一下衛(wèi)生保健的費用，我想我們每個人都有責任，應該將其控制在一定的范圍之內(nèi)。那是由人□特征決定的，由老齡人□決定的，和其他地區(qū)出現(xiàn)的中產(chǎn)階級決定的。人們想要生活得更久、更好、更健康，所以我認為我們肩負一定的責任。首先我們應該去看一下預防和保健，那些健康的人們是如何保健的，并且給予他們必要的治療，所以衛(wèi)生保健的費用是一個很大的挑戰(zhàn)。我想，公司的監(jiān)管環(huán)境也將是一個很大的挑戰(zhàn)。人們現(xiàn)在正在追求零風險的產(chǎn)品，然而當你早上起床后，走在街上，這也不是一件零風險的事情。所以零風險的產(chǎn)品是很難得到的。藥物，顧名思義就有好的效果以及副作用。我曾經(jīng)將自己的膝蓋替換過，每個人都知道那將會有風險，我的替換的膝蓋現(xiàn)在證明很好，但是它其實也有不好的可能。有很多這樣的事情，我想每個人都在尋找一個零風險的環(huán)境，但是實際上它并不是沒有風險的，無論什么事情總會伴隨有 一定的風險，我們必須要清楚地對此進行界定。我們必須要作詳細的研究與調(diào)查，研究那些藥物以及它們的效果。但我認為，監(jiān)管環(huán)境在試圖找出所有問題時也變得有些不愿意接受風險。通常對于病人是那樣的，但是很多時候由于人們使用產(chǎn)品的方式你并不能發(fā)現(xiàn)所有問題。